Intelligence Feed event · Equity · 2026-09-28

    HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate

    Question

    HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate

    Direct answer

    HUTCHMED announced that the first patient was dosed on September 24, 2026, in its Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate is a first-in-class dual-mechanism antibody-targeted therapy conjugate engineered to link a potent KRAS inhibitor with an anti-EGFR monoclonal antibody. The trial is evaluating safety, tolerability, pharmacokinetics, and preliminary antineoplastic activity across solid tumor types known to harbor KRAS mutations with EGFR overexpression. HUTCHMED is advancing the clinical program under an exclusive global collaboration and commercial licensing agreement with GSK.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-28
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate”, revision 1, evidence through 2026-09-28. https://marketontology.com/market-events/2026-09-28/hutchmed-initiates-phase-ia-global-trial-of-first-in-class-kras-egfr-conjugate-52f8b2

    EQUITY
    HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate
    HUTCHMED announced that the first patient was dosed on September 24, 2026, in its Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate is a first-in-class dual-mechanism antibody-targeted therapy conjugate engineered to link a potent KRAS inhibitor with an anti-EGFR monoclonal antibody. The trial is evaluating safety, tolerability, pharmacokinetics, and preliminary antineoplastic activity across solid tumor types known to harbor KRAS mutations with EGFR overexpression. HUTCHMED is advancing the clinical program under an exclusive global collaboration and commercial licensing agreement with GSK.
    HCMGSK
    Impact
    63
    SEP 28
    SIG
    90%
    HCMGSK
    HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate
    HUTCHMED announced that the first patient was dosed on September 24, 2026, in its Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate is a first-in-class dual-mechanism antibody-targeted therapy conjugate engineered to link a potent KRAS inhibitor with an anti-EGFR monoclonal antibody. The trial is evaluating safety, tolerability, pharmacokinetics, and preliminary antineoplastic activity across solid tumor types known to harbor KRAS mutations with EGFR overexpression. HUTCHMED is advancing the clinical program under an exclusive global collaboration and commercial licensing agreement with GSK.
    → Phase Ia clinical dose escalation initiates regulatory milestone eligibility and validation data for HCM under its GSK development partnership.
    Impact
    HUTCHMED announced that the first patient was dosed on September 24, 2026, in its Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate is a first-in-class dual-mechanism antibody-targeted therapy conjugate engineered to link a potent KRAS inhibitor with an anti-EGFR monoclonal antibody. The trial is evaluating safety, tolerability, pharmacokinetics, and preliminary antineoplastic activity across solid tumor types known to harbor KRAS mutations with EGFR overexpression. HUTCHMED is advancing the clinical program under an exclusive global collaboration and commercial licensing agreement with GSK.
    Affected
    HCMGSK
    Transmission
    Phase Ia clinical dose escalation initiates regulatory milestone eligibility and validation data for HCM under its GSK development partnership.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMclinical pipeline milestone progression and milestone fee eligibilityUp1-3mFirst patient dosed in Phase Ia global trial of HMPL-A830
    GSKexpansion of targeted oncology pipeline assetsUp1-3mGSK holds exclusive development and commercialization rights with HUTCHMED

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed14.13 2026-09-28+0.14%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month